Form 8-K

8-K — GYRE THERAPEUTICS, INC.

Accession: 0001140361-26-035189

Filed: 2026-09-01

Period: 2026-09-01

CIK: 0001124105

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ef20081441_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ef20081441_ex99-1.htm)

GRAPHIC (ef20081441_ex99-1slide1.jpg)

GRAPHIC (ef20081441_ex99-1slide2.jpg)

GRAPHIC (ef20081441_ex99-1slide3.jpg)

GRAPHIC (ef20081441_ex99-1slide4.jpg)

GRAPHIC (ef20081441_ex99-1slide5.jpg)

GRAPHIC (ef20081441_ex99-1slide6.jpg)

GRAPHIC (ef20081441_ex99-1slide7.jpg)

GRAPHIC (ef20081441_ex99-1slide8.jpg)

GRAPHIC (ef20081441_ex99-1slide9.jpg)

GRAPHIC (ef20081441_ex99-1slide10.jpg)

GRAPHIC (ef20081441_ex99-1slide11.jpg)

GRAPHIC (ef20081441_ex99-1slide12.jpg)

GRAPHIC (ef20081441_ex99-1slide13.jpg)

GRAPHIC (ef20081441_ex99-1slide14.jpg)

GRAPHIC (ef20081441_ex99-1slide15.jpg)

GRAPHIC (ef20081441_ex99-1slide16.jpg)

GRAPHIC (ef20081441_ex99-1slide17.jpg)

GRAPHIC (ef20081441_ex99-1slide18.jpg)

GRAPHIC (ef20081441_ex99-1slide19.jpg)

GRAPHIC (ef20081441_ex99-1slide20.jpg)

GRAPHIC (ef20081441_ex99-1slide21.jpg)

GRAPHIC (ef20081441_ex99-1slide22.jpg)

GRAPHIC (ef20081441_ex99-1slide23.jpg)

GRAPHIC (ef20081441_ex99-1slide24.jpg)

GRAPHIC (ef20081441_ex99-1slide25.jpg)

GRAPHIC (ef20081441_ex99-1slide26.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20081441_8k.htm · Sequence: 1

false0001124105NASDAQ00011241052026-09-012026-09-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 1, 2026

Gyre Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-51173

56-2020050

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

12730 High Bluff Drive

Suite 250

San Diego, CA

92130

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (858) 284-0115

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock

GYRE

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this

chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new

or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On September 1, 2026, Gyre Therapeutics, Inc. (the “Company”) made available an updated corporate presentation on the Company’s website.

A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit

furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that

section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Exhibit Title or Description

99.1

Corporate Presentation, dated September 2026

104

Cover page interactive data file (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on

its behalf by the undersigned hereunto duly authorized.

GYRE THERAPEUTICS, INC.

Date: September 1, 2026

By:

/s/ Thomas Eastling

Name:

Thomas Eastling

Title:

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20081441_ex99-1.htm · Sequence: 2

Exhibit 99.1

1 September 2026 A Global Innovator Expanding And Reinventing Protein Degrader

Therapeutics

This presentation contains “forward-looking statements” within the meaning of

the federal securities laws, including Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the current plans, expectations and strategies of Gyre

Therapeutics, Inc. and its subsidiaries (“Gyre”), which statements are subject to substantial risks and uncertainties and are based on management’s estimates and assumptions. All statements, other than statements of historical facts included

in this presentation, are forward-looking statements, including Gyre’s ability to leverage China operations for discovery, validation and development of therapeutics, clinical development plans, anticipated timelines and milestones of Gyre’s

degrader antibody-conjugate platform, CG923308, CG620953, CG009301, CG001419, F351 and ETUARYTM, including the geographic location and timing of anticipated regulatory submissions and approvals, and the potential therapeutic benefits,

efficacy, safety and differentiation of such product candidates, and market size and commercial opportunity estimates, Gyre’s plans, objectives, goals, strategies, future events, or intentions relating to Gyre’s products and markets, the

safety, efficacy and clinical benefits of Gyre’s product candidates, the anticipated timing and design of any planned and ongoing preclinical studies and clinical trials, Gyre’s research and development efforts, plans and objectives of

management for future operations and future results of anticipated product development efforts, potential addressable market size and Gyre’s liquidity and capital resources and business trends. In some cases, you can identify forward-looking

statements by terms such as “believe,” “can,” “could,” “anticipate”, “design,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “target”, “seek”, “goal”, “assume”, “milestones”, “potential,” “predict,” “objective,”

“should,” “strategy,” “will,” “would,” “forthcoming,” or the negative of these terms, and similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements may include express or implied

statements relating to: the estimated future financial performance and financial position of Gyre; the therapeutic potential and utility, efficacy and clinical benefits of the product candidates of Gyre; the risk/benefit profile of Gyre’s

product candidates; expectations regarding Gyre’s research and development efforts, including geographic location and timing of initiation of clinical trials for Gyre’s product candidates; Gyre’s expectations regarding the advancement of

product candidates into IND-enabling studies; and Gyre’s expectations, hopes, beliefs, intentions and strategies; and other statements that are not historical fact. These statements involve known and unknown risks, uncertainties and other

factors that could cause Gyre’s actual results to differ materially from the forward-looking statements expressed or implied in this presentation, in addition to those risks and uncertainties, such as the uncertainties inherent in the

clinical drug development process, the regulatory approval process, the timing of any regulatory filings, the potential for substantial delays, the risk that earlier study results may not be predictive of future study results, manufacturing

risks, competition from other therapies or products and the impacts of current macroeconomic and geopolitical risks. A discussion of these and other factors, is set forth in Gyre’s Annual Report on Form 10-K for the year ended December 31,

2025 filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2026 and elsewhere in such other filings and in Gyre’s periodic reports and subsequent disclosure documents filed with the SEC. Gyre cannot assure you that it

will realize the results, benefits or developments that it expects or anticipates or, even if substantially realized, that they will result in the consequences or affect Gyre or its business in the way expected. Forward-looking statements are

not historical facts and reflect management’s current views with respect to future events. Given the significant uncertainties, you should evaluate all forward-looking statements in the context of these risks and uncertainties and not place

undue reliance on these forward-looking statements as predictions of future events. All forward-looking statements in this presentation apply only as of the date made and are expressly qualified in their entirety by the cautionary statements

included in this presentation. Gyre has no intention to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by law. Certain information contained in this presentation and

statements made orally during this presentation relate to or is based on studies, publications, surveys and other data obtained from third-party sources and Gyre’s own internal estimates and research. While Gyre believes these third-party

studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information

obtained from third-party sources. In addition, no independent sources have evaluated the reasonableness or accuracy of Gyre’s internal estimates or research, and no reliance should be made on any information or statements made in this

presentation relating to or based on such internal estimates and research. This presentation contains trademarks, trade names and service marks of other companies which are the property of their respective owners. This presentation concerns a

discussion of investigational drugs that are under preclinical and/or clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to

investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated. 2 Forward-looking Statements

3 Gyre Is A Global Development Engine Fueled by its China Discovery and

Commercialization Platform Value Drivers Key Features Details A Commercial Foundation and Integrated U.S. – China R&D Engine Support Capital-Efficient Advancement of a Diversified Pipeline Growth Opportunities Established Innovation

Engine Global Infrastructure Commercial Footprint Diversified R&D programs spanning across multiple indications Both early- and late-stage pipeline assets provide near- and long-term catalysts Supports next-generation TPD and DAC

platform development Fully-integrated R&D capabilities Leveraging cost-efficient China operations for accelerated discovery, preclinical validation, and early clinical-stage development ETUARYTM has been the market-leading pirfenidone

brand in China for treatment of idiopathic pulmonary fibrosis (IPF) F351 adds a near-term revenue growth catalyst for the China commercial portfolio Degrader platform for the development of TPDs & DACs Dual degraders for

oncology/I&I DACs in pre-IND studies ETUARYTM FY26 Total Revenue Guidance $100.5M-$111M F351 potential launch in early 27’ San Diego: Headquarters Shanghai: Discovery Beijing: Manufacturing & Sales *TPDs = targeted protein

degraders; DACs = degrader antibody conjugates

4 Gyre’s Flexible, Capital-Efficient Global Development Strategy China Revenue

Builds & De-Risks the Early Pipeline U.S. Capital Advances Priority Assets Globally Cash-flow Generation: Established commercial operations in China to help offset cash burn. Reinvestment to R&D Engine: China-generated cash funds

preclinical development quickly, at scale, and cost-efficiently, leveraging Gyre’s already-established China infrastructure. Translational De-risking: Conduct broader preclinical and translational studies to select strongest candidates and

build IND-enabling packages. Focused Capital Allocation: U.S.-raised capital invests into the highest-priority U.S. and global clinical programs. Flexible Clinical Routing: Initiate studies in the U.S., China or both based on the most

efficient development path. Pivotal Development and Launch: Advance selected assets through U.S. and global clinical studies, pivotal trials, regulatory approvals and launch.

Global Development Programs and Upcoming Catalysts Program and

Description Indication Pre-IND Studies Phase 1 Phase 2 Phase 3 NDA Submitted Catalyst DAC Platform / Next-Gen Degrader Technologies Oncology / Inflammatory Disease Discovery Platform Lead DAC selection / IND-enabling

advancement CDK2 / Cyclin E DegraderCG923308 CDK4/6i-resistant Breast Cancer and Other Solid Tumors Q1’27 IND-application submission in U.S. and/or China; Phase 1 start in 2027 TYK2 / JAK 1 Degrader CG620953 Systemic Lupus Erythematosus

(SLE) & Rheumatoid Arthritis (RA) Q1’27 IND-application submission in U.S. and/or China; Phase 1 start in 2027 GSPT1 Degrader CG009301 R/R AML, HR-MDS, R/R ALL; Solid Tumor Cancers Phase 1 data in patients with high-risk hematologic

malignancies expected at trial completion TRK Degrader CG001419 Cancer-induced Bone Pain (CIBP) Planning Phase 2 initiation in U.S. or China Hydronidone F351 Chronic Hepatitis B (CHB)-induced Liver Fibrosis NDA-filing accepted by China

NMPA in May 2026; Potential launch post-NMPA decision in early 2027 Inflammation / Fibrosis Cancer Degrader DAC China R&D incubator provides new promising clinical assets for global development in cancer, immunology &

inflammatory (I&I) diseases, and pain 5 Discovery & lead selection in China IND-enabling development in China; Phase 1 in U.S. and/or China IND-enabling development in China; Phase 1 in U.S. and/or China Phase 1 dose escalation

ongoing in China Phase 1 in healthy volunteers completed in Australia; Phase 2 in U.S. or China

7 A Modular Degrader Platform: From Discovery to Clinic One Platform. Multiple

Degraders. Built for Broad Impact Across Oncology and Immunology. Gyre’s Proprietary Targeted Protein Degraders’ Catalytic Mechanism of Action Enables: High Potency Access to Undruggable Targets Modular Design to Create Multiple

Degraders Our expertise also translates well into implementing TPD technology into Antibody-drug conjugates (ADCs) to make next-gen ADCs, called Degrader Antibody Conjugates (DACs). Ubiquitin Proteasome System (UPS) – Our Engine for

Targeted Protein Degradation Disease causing protein Lys E3 ligase Degrader Disease causing protein Lys E3 ligase RING Ub Ub Ub Ub Ub E2 Gyre’s Targeted Protein Degrader Molecule Identifying & Binding Tagging

Disease Protein Disease-Causing protein being degraded by the proteasome Degraded protein Proteasome Ubiquitin Chain Disease-causing protein

8 CDK2-Cyclin E Dual Degrader: Novel Strategy for Multiple Solid Cancer

Types Cyclin E Is Functionally Amplified or Overexpressed Across Multiple Cancer Types :[1] Lee et al (2026) Clin Cancer Res. PMID:41870274 [1] Turner NC (2019) J Clin Oncol. PMID: 30807234; [2] Herrera-Abreu MT (2016) Cancer Res. PMID:

27020857; [3] Costa C (2020) Cancer Discov. PMID: 31594766 [4] Freeman-Cook (2021) Cancer Cell. PMID: 34520734; [5] Wander SA (2020) Cancer Discov. PMID: 32404308; [6] Al-Qasem AJ(2022) NPJ Precis Oncol. 2022 PMID: 36153348 [7] Josefine B

(2012) Breast Cancer Res Treat. PMID: 23242584; [8] Caldon CE (2012) Mol. Cancer Ther. PMID: 22564725 Diverse CDK4/6i or Endocrine Therapy Resistance Converge on Activation of CDK2/Cyclin E N = 486,340 CDK2-Cyclin E Dual Degrader Cyclin E

overexpression CCNE amplification Rb loss PTEN loss PI3K upregulation MYC overexpression Erα alterations ET Resistance CDK2/ cyclin E CDK4/6i Resistance [1, 4, 5] [6] [2,4] [2,5] [3] [2] [7] [4] [8] CCNE1 Amplification

Prevalence (%) [1] Market Opportunity & Unmet Medical Need Verzenio, Kisqali, and Ibrance ~$14.6B Total Global Revenues in 2025 Projected total global revenues between $25.8B - $35.7B by early 2030s ~50% of patients develop

resistance to CDK4/6 inhibitors within 2 years of starting therapy Strategic Market Research, July 2026 CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1

CG923308 Demonstrates Anti-Cancer Efficacy in Resistant Preclinical

Models 9 CG923308 produces meaningful anti-cancer efficacy in multiple solid tumor preclinical mouse models, including CDK4/6i-resistant models MKN1 Gastric CDX HCC1599 TNBC CDX OVCAR3 Ovarian CDX CDK4/6i-resistant MCF7

CDX CDK4/6i-resistant breast PDX INCB123667: A phase 2/3 CDK2 inhibitor by Incyte; Palbo: Palbociclib (Ibrance), CDK4/6 inhibitor developed by Pfizer; TQB3616: CDK2/4/6 inhibitor developed by Chia Tai Tianqing; TNBC: triple-negative breast

cancer CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 A. Ovarian Cancer CDX C. Gastric Cancer CDX D. TNBC CDX B. Chemo-resistant TNBC PDX E. CDK4/6i-resistant breast cancer CDX F. CDK4/6i-resistant breast cancer PDX

Chronic Inflammation and Autoimmune Diseases 10 TYK2-JAK1 Dual Degrader:

Next-Generation Therapy for Autoimmune Diseases Notes: https://www.psoriasis.org/psoriasis-statistics/ https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis;

https://www.niams.nih.gov/health-topics/lupus/basics/symptoms-causes; Significant Unmet Need and Market Opportunity Across Autoimmune Diseases Cytokine signaling mediated by TYK2 and JAK1 125MM+ Patients

Worldwide(1) Psoriasis 18MM Patients Worldwide(2) Rheumatoid Arthritis 204K+ Patients U.S.(3) Systemic Lupus Erythematosus Other Inflammatory and Autoimmune Indications IL-12 Drives Th1 differentiation and

activation IL-23 Drives Th17 differentiation and maintenance Type I IFNs Antiviral response and inflammation TYK2 JAK2 TYK2 JAK1 STAT Activation Pro-inflammatory Gene Expression TYK2 TYK2 JAK1 + (Heterodimer) CDK2 / Cyclin

E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 Efficacy High Broad / keydisease-drivingcytokines Low Limited relevanceto core IMIDpathways Safety High Risk (severe immunosuppression,hematologic, infection, others) Low Risk (more

favorable safety profile) JAK1 JAK3 JAK2 TYK2 TYK2 & JAK1 ✓ Broad disease coverage ✓ Synergistic activity via dual degradation enhances efficacy ✓ Sparing JAK2 and JAK3 leads to a favorable safety profile Sweet Spot of TYK2/JAK1

Dual Targeting

CG620953 Demonstrates Efficacy in Lupus and RA Preclinical

Models 11 Lupus RA CG620953 exhibit enhanced efficacy signals in preclinical models CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 Sotyktu (10 mpk, qd, po) Disease model 10 mpk Control 30 mpk 60 mpk CG620953 (qd,

po) Nose lesion score Percent of survival Days since dosing Control-vehicle Disease model CG620953 (10 mpk, qd, po) CG620953 (30 mpk, qd, po) CG620953 (60 mpk, qd, po) Deucravacitinib (10 mpk, qd, po) Survival rate Doral skin

lesion score Kidney injury histopathology Kidney histopathological Score Disease model 10 mpk Control 30 mpk 60 mpk CG620953 (qd, po) Vehicle Sotyktu (10 mpk, qd, po) Joint thickness (mm) Control Disease model CG620953 (30

mpk, qd, po) Tofacitinib (10 mpk, qd, po) Days since dosing Joint inflammation & cartilage destruction Days since dosing Plantar thickness (mm) Control Disease model CG620953 (30 mpk, qd, po) Tofacitinib (10 mpk, qd, po) Hind

paw edema TYK2/JAK1 degradation & JAK2/3 sparing

Pan-TRK Degrader: Potential First-in-Class, Non-Opioid Therapeutic Degrader for

Cancer-Induced Bone Pain 1. https://pubmed.ncbi.nlm.nih.gov/22570568 2. https://pubmed.ncbi.nlm.nih.gov/26229504 3. https://pubmed.ncbi.nlm.nih.gov/23344095 4. https://pubmed.ncbi.nlm.nih.gov/25919474 5.

https://pubmed.ncbi.nlm.nih.gov/37343145 CG001419 Oral Pan-TRK Degrader Degrades TrkA at the source Phase 1a target engagement in high single-digit / low double-digit nanomolar ranges. Well-tolerated up to highest dose

tested.6 U.S.‒China clinical development enables parallel execution and faster timelines Differentiated Mechanism Early Clinical Validation Speed Advantage 12 New cases of malignant bone metastasis in the U.S. annually 1,2 280K –

330K 70-90% develop symptomatic pain with limited current treatment options 3 Significant Unmet Need Average treatment duration for cancer-induced bone pain 4,5 193-225 Days CDK2 / Cyclin E TYK2 /

JAK1 TRK DAC Fibrosis GSPT1 Cancer-Induced Bone Pain U.S. Market Opportunity Our Differentiated Approach 6. Company data; CG001419-101 (NCT06636500).

13 CG001419 Phase 1 Results: PD Target Engagement and Safety Source: Company

data; CG001419-101 (NCT06636500). Safety / Tolerability from Phase 1 Pharmacodynamics: potential target engagement demonstrated Plasma-to-reporter cell assay showed TRKA degradation, supporting potential target engagement Potent surrogate

PD activity observed: DC50 = 2.1 ng/mL; DC90 = 16 ng/mL Favorable safety / tolerability profile Single and multiple oral doses were well tolerated up to the highest tested dose levels Most TEAEs were mild or moderate; no Grade 4 TEAEs

reported Common TEAEs were largely general / administration-site events, likely related to blood collection procedures Predictable exposure profile supports continued development Single-dose CG001419 exposure increased

dose-proportionally Fed condition increased systemic exposure; 7-day MAD exposure increased less than dose-proportionally for CG001419 and metabolites M2/M8 Surrogate PD Assay Demonstrated Degradation Potency in the Low-nM

Range. GFP TRKA Patient Plasma Reporter Cell Line DC50 = 2.1 ng/mL DC90 = 16 ng/mL Completed Phase 1 studies in healthy volunteers; currently planning Phase 2 for cancer-induced bone pain to commence in U.S. or China CDK2 / Cyclin

E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 Multiple Ascending Dose (MAD) PK – Day 7 Pharmacodynamics: Potential Target Engagement

14 CG009301: Targeting GSPT1 for AML and Solid Tumor Cancers GSPT1 controls

protein translation termination and plays important function for leukemia stem cells and tumor cells with MYC overproduction GSPT1 lacks an active site and is often considered “undruggable” Other programs targeting GSPT1 show insufficient

therapeutic index. CG009301 demonstrate encouraging safety profile in our preclinical studies and early clinical development. Notes: 2024 by American Cancer Society estimates The Cancer Genome Atlas (TCGA) estimates Schaub et al (2018)

Cell Syst PMID: 295967830 Volpe et al. (2022) Clin Lymphoa Myelom Leuk, PMID: 34544674 GTP Hydrolysis Peptide Release GTP GSPT1 60S 40S eRF1 GDP GSPT1 60S 40S eRF1 GDP GSPT1 60S 40S eRF1 Global Blood Cancer Treatment

Market Size, by Treatment Type, 2023-2033 (USD Bn) U.S. Patient Population ~20,800 new cases ~10,000 new cases ~6,500 new cases 28% 11,220 mortality 1,330 mortality 30-40% MDS progress to AML (4) AML (1) MDS (1) ALL

(1) MYC-amplified Solid Tumors (2),(3) The Market will Grow 10.3% The Forecasted Market 15.7Bn At the CAGR of: size for 2033 in US$: CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1

15 CG009301: Ongoing Phase 1 in China for patients with high-risk heme

malignancies CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 Dose Escalation Dose Expansion RP2D Dose X：xx mg, n=9~18 Dose X：xx mg, n=9~18 28 days as one cycle R/R-AML, HR-MDS & R/R-ALL Recurrent or refractory

haematological malignancies 50-86 subjects BOIN Design Rapid titration Dose level 1 - mg QD, n =1 Dose level 2 - mg QD, n=1 Dose level 3 - mg QD, n=3 Dose level 6 - mg QD,n=6~12 Dose level 7 - mg QD,n=6~12 Dose level 8 - mg

QD,n=xx Dose level 4 - mg QD, n=3~6 Dose level 5 - mg QD,n=3~6 Dose level 9 - mg QD,n=xx Dose level 10 - mg QD,n=xx Dose level 2 - mg QD, n=3 Dose level 3a - mg QD,n=3~6 Dose level 2a - mg QD, n=3~6 Dose level 3 - mg QD,n=3~6 D1-7

each cycle iv. administration BOIN Design D1-14 each cycle iv. administration

Degrader-Antibody Conjugates (DACs)

Leveraging Expertise in TPDs and China ADC Platform to Develop Degrader-Antibody

Conjugates (DACs) Gyre’s DAC Platform for Multiple Cancer Types HIGH POTENCY IMPROVED pk Gyre’s DAC Mechanism of Action & Benefits EnhancED SAFETY 17 CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 mAbs – monoclonal

antibodies TAAs – Tumor-assisted Antigens

Gyre’s DACs Demonstrate Broad Efficacy Across Diverse Tumor Types mAb:

monoclonal antibody recognizing a specific antigen; DXd-ADC: HER2-DXd ADC (Enhertu) Developed by Daiichi Sankyo and AstraZeneca 18 CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 A. AML CDX model B. AML CDX model C. Breast Cancer

model D. Breast Cancer model E. Prostate Cancer CDX model F. NSCLC CDX model

DAC for Prostate Cancer and Solid Tumors With An Epigenetic-Targeting

Payload Therapeutic-resistant PDX model Prostate cancer CDX model Non-human primate pilot toxicity Prostate cancer causes 35,000 – 36,500 deaths each year and is the second-leading cause of cancer death in the US.1 Epigenetic factors are

frequently mutated across human malignancies, including prostate cancer. Prior developments targeting epigenetic factors for prostate cancer has been limited by the toxicity. Protein degradation & cytotoxicity 19 CDK2 / Cyclin

E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 American Cancer Society estimates as of August 2026

Commercial Foundation and Growth Opportunities with F351 (Hydronidone)

ETUARYTM: The Commercial Anchor of Our Fibrosis Franchise Since 2011 A Durable

Revenue Base that Funds Innovation and Supports Our Next-generation Degrader / DAC Platform Notes: 1. ETUARY market position based on IQVIA CHPA data for pirfenidone in China [2014-2026]: legal review required. Financial data inclusive of

pro forma data prior to GNI Group and Catalyst Biosciences business combination. 2017 sales in audited China GAAP; 2025 in audited U.S. GAAP 21 Established Leadership ETUARYTM has anchored our IPF franchise in China through consistent

execution and broad physician reach, supported by ῀370 commercial personnel across 3,000+ hospitals and pharmacies. Durable Market Position ETUARYTM was approved by NMPA in 2011 before Esbriet approval by US FDA. GYRE Pharmaceuticals has

maintained market leadership positions in China since then, which demonstrated GYRE’s capability to manage the drug life cycle. Funds the Innovation Pipeline ETUARYTM's recurring commercial revenue supports our next-generation degrader /

DAC platform without dilution dependence.    ETUARYTM (Pirfenidone) (1) 1 Etorel TM – Launched in 2025 2 F351 (Hydronidone) 3 China’s Leading Pirfenidone Brand For the Treatment of IPF (1) Complementary PF option that extends

the fibrosis toolkit alongside ETUARYTM. NDA accepted for priority review by NMPA in May 2026. A One-stop Shop for Fibrosis – Building Physician Reach Ahead of F351 CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1

Breakthrough Therapy Designation Priority Review of NDA (China NMPA, 2021,

2026) NDA accepted by NMPA in May 2026 22 F351 Phase 3 Results in CHB-associated Liver Fibrosis Supports Regulatory Filing Primary Endpoint Met with High Statistical Significance ≥1-stage fibrosis regression at Week 52: F351: 52.85%

(n=123) vs. Placebo: 29.84% (n=124) Delta: 23.01% p = 0.0002 (ITT analysis with central blinded pathology review) Consistent with fibrosis regression rates observed in Phase 2 Key Secondary Endpoint Reduction in Liver

Inflammation ≥1-grade inflammation improvement without fibrosis progression at Week 52: F351: 49.57% (n=123) vs. Placebo: 34.82% (n=124) Delta: 14.75% p = 0.0246 Reinforces anti-inflammatory activity CDK2 / Cyclin E TYK2 /

JAK1 TRK DAC Fibrosis GSPT1 F351 poised to be the next-generation of fibrosis therapy

China-First Strategy Provides Accelerated POC 23 MASH Fibrosis Market Provides

Significant Upside Opportunity For F351 Forecasted Market Size of MASH Fibrosis Therapies in the USA ($MM USD) USA MASH Therapeutics Sales forecast from Evaluate Pharma as of 5-13-2026 Assumes 50% of all MASH patients progress to MASH

fibrosis (Stage ≥F2) based on Luthra & Sheth (2025). Note: 1. Le et al. (2025) JAMA; AJMC; MASH Awareness; Estes et al. (2018) AASLD; L.E.K. interviews Current U.S. MASH prevalence is estimated at ~14MM (1) MASH represents tremendous

growth opportunity due to very low current MASH diagnosis rate (5-10%) Rising obesity and diabetes increase MASH progression via liver inflammation 42% CAGR (2025 – 2032) CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1

24 Key Value Drivers Lead TPD Assets Opportunities in cancer and autoimmune

diseases with dual degraders TPD portfolio highly validated for large unmet need indications TPD / DAC R&D Engine Multiple shots on goal DACs paint a promising picture as the next-gen to ADCs / TPDs alone Global Exposure Lean

operations to de-risk assets U.S. headquarters and integrated U.S. and China R&D operations Revenues to Support Operations ETUARYTM and anticipated F351 sales in China expected to cover operation expenses to support early-stage R&D

and proof-of-concepts studies 1 2 3 4

U.S. Management Team with Cross-Culture Operational Experience Ying Luo,

Ph.D. Chief Executive Officer Thomas Eastling Chief Financial Officer Weiguo Ye Chief Operating Officer Yue Xiong, Ph.D. Chief Scientific Officer Ruoyu Chen Chief Information Officer Jialiang Wang, Ph.D. Executive Vice

President, General Manager Joshua Bergmann, J.D. General Counsel and Corporate Secretary Seth Goldblum, MBA Senior Vice President – Corporate Development Jing Liu, Ph.D. Senior Vice President – Platform Chemistry Michael Plewe,

Ph.D. Senior Vice President - Medicinal Chemistry Mark Marino, M.D. Senior Vice President –Clinical Development Leslie Robinson, Ph.D., J.D. Vice President - Intellectual Property and Licensing Liang Zhao Vice President – Corporate

Controller Sudan Loganathan, Ph.D. Vice President – Investor Relations & Finance Strategy Chuck Monahan Senior Vice President – Regulatory Affairs

Thank You!

GRAPHIC

Filename: ef20081441_ex99-1slide1.jpg · Sequence: 6

Binary file (88520 bytes)

Download ef20081441_ex99-1slide1.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide2.jpg · Sequence: 7

Binary file (275858 bytes)

Download ef20081441_ex99-1slide2.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide3.jpg · Sequence: 8

Binary file (150678 bytes)

Download ef20081441_ex99-1slide3.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide4.jpg · Sequence: 9

Binary file (124650 bytes)

Download ef20081441_ex99-1slide4.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide5.jpg · Sequence: 10

Binary file (150144 bytes)

Download ef20081441_ex99-1slide5.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide6.jpg · Sequence: 11

Binary file (59458 bytes)

Download ef20081441_ex99-1slide6.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide7.jpg · Sequence: 12

Binary file (132127 bytes)

Download ef20081441_ex99-1slide7.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide8.jpg · Sequence: 13

Binary file (144646 bytes)

Download ef20081441_ex99-1slide8.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide9.jpg · Sequence: 14

Binary file (155572 bytes)

Download ef20081441_ex99-1slide9.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide10.jpg · Sequence: 15

Binary file (133786 bytes)

Download ef20081441_ex99-1slide10.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide11.jpg · Sequence: 16

Binary file (138214 bytes)

Download ef20081441_ex99-1slide11.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide12.jpg · Sequence: 17

Binary file (122293 bytes)

Download ef20081441_ex99-1slide12.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide13.jpg · Sequence: 18

Binary file (158317 bytes)

Download ef20081441_ex99-1slide13.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide14.jpg · Sequence: 19

Binary file (140151 bytes)

Download ef20081441_ex99-1slide14.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide15.jpg · Sequence: 20

Binary file (113290 bytes)

Download ef20081441_ex99-1slide15.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide16.jpg · Sequence: 21

Binary file (59301 bytes)

Download ef20081441_ex99-1slide16.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide17.jpg · Sequence: 22

Binary file (134975 bytes)

Download ef20081441_ex99-1slide17.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide18.jpg · Sequence: 23

Binary file (146731 bytes)

Download ef20081441_ex99-1slide18.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide19.jpg · Sequence: 24

Binary file (137531 bytes)

Download ef20081441_ex99-1slide19.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide20.jpg · Sequence: 25

Binary file (68093 bytes)

Download ef20081441_ex99-1slide20.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide21.jpg · Sequence: 26

Binary file (143606 bytes)

Download ef20081441_ex99-1slide21.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide22.jpg · Sequence: 27

Binary file (115894 bytes)

Download ef20081441_ex99-1slide22.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide23.jpg · Sequence: 28

Binary file (113776 bytes)

Download ef20081441_ex99-1slide23.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide24.jpg · Sequence: 29

Binary file (99260 bytes)

Download ef20081441_ex99-1slide24.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide25.jpg · Sequence: 30

Binary file (126942 bytes)

Download ef20081441_ex99-1slide25.jpg

GRAPHIC

Filename: ef20081441_ex99-1slide26.jpg · Sequence: 31

Binary file (66610 bytes)

Download ef20081441_ex99-1slide26.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 33

v3.26.1

Document and Entity Information

Sep. 01, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 01, 2026

Entity File Number

000-51173

Entity Registrant Name

Gyre Therapeutics, Inc.

Entity Central Index Key

0001124105

Entity Incorporation, State or Country Code

Entity Tax Identification Number

56-2020050

Entity Address, Address Line One

12730 High Bluff Drive

Entity Address, Address Line Two

Suite 250

Entity Address, City or Town

San Diego

Entity Address, State or Province

Entity Address, Postal Zip Code

92130

City Area Code

858

Local Phone Number

284-0115

Title of 12(b) Security

Common Stock

Trading Symbol

GYRE

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration